Investig Clin Urol.  2020 Feb;61(Suppl 1):S33-S42. 10.4111/icu.2020.61.S1.S33.

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis

• Chen JL
• Kuo HC

• KMID: 2469124
• DOI: http://doi.org/10.4111/icu.2020.61.S1.S33

Abstract

After decades of clinical and basic science research, the clinical application of botulinum toxin A (Botox) in urology has been extended to neurogenic detrusor overactivity (NDO), idiopathic detrusor overactivity, refractory overactive bladder (OAB), interstitial cystitis/bladder pain syndrome (IC/BPS), lower urinary tract symptoms, benign prostatic hyperplasia, and neurogenic or non-neurogenic lower urinary tract dysfunction in children. Botox selectively disrupts and modulates neurotransmission, suppresses detrusor overactivity, and modulates sensory function, inflammation, and glandular function. In addition to motor effects, Botox has been found to have sensory inhibitory effects and anti-inflammatory effects; therefore, it has been used to treat IC/BPS and OAB. Currently, Botox has been approved for the treatment of NDO and OAB. Recent clinical trials on Botox for the treatment of IC/BPS have reported promising therapeutic effects, including reduced bladder pain. Additionally, the therapeutic duration was found to be longer with repeated Botox injections than with a single injection. However, the use of Botox for IC/BPS has not been approved. This paper reviews the recent advances in intravesical Botox treatment for OAB and IC/BPS.

Keyword

Botulinum toxins, type A; Cystitis, interstitial; Therapeutics; Urinary bladder, overactive

MeSH Terms

Botulinum Toxins*
Botulinum Toxins, Type A*
Child
Cystitis, Interstitial*
Humans
Inflammation
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Sensation
Synaptic Transmission
Therapeutic Uses
Urinary Bladder
Urinary Bladder, Overactive*
Urinary Tract
Urology
Botulinum Toxins
Botulinum Toxins, Type A
Therapeutic Uses

Reference

1. Dykstra DD, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988; 139:919–922.

2. Schurch B, Hauri D, Rodic B, Curt A, Meyer M, Rossier AB. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996; 155:1023–1029.

3. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990; 71:24–26.

4. de Sèze M, Petit H, Gallien P, de Sèze MP, Joseph PA, Mazaux JM, et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur Urol. 2002; 42:56–62.

5. Kuo HC. Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction. Ci Ji Yi Xue Za Zhi. 2016; 28:89–93.

6. Kuo HC. Individualizing medical treatment of overactive bladder. Ci Ji Yi Xue Za Zhi. 2018; 30:195–199.

7. Kuo HC. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology. 2005; 66:94–98.

8. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000; 164(3 Pt 1):692–697.

9. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004; 45:510–515.

10. Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004; 19 Suppl 8:S2–S6.

11. Schiavo G, Rossetto O, Santucci A, DasGupta BR, Montecucco C. Botulinum neurotoxins are zinc proteins. J Biol Chem. 1992; 267:23479–23483.

12. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006; 312:592–596.

13. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol. 1986; 26:427–453.

14. Smith CP, Gangitano DA, Munoz A, Salas NA, Boone TB, Aoki KR, et al. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int. 2008; 52:1068–1075.

15. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008; 101:366–370.

16. Yiangou Y, Facer P, Ford A, Brady C, Wiseman O, Fowler CJ, et al. Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int. 2001; 87:774–779.

17. Dolly JO, O'Connell MA. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol. 2012; 12:100–108.

18. Guo BL, Zheng CX, Sui BD, Li YQ, Wang YY, Yang YL. A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon. 2013; 71:134–139.

19. Steers WD, Kolbeck S, Creedon D, Tuttle JB. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J Clin Invest. 1991; 88:1709–1715.

20. Dupont MC, Spitsbergen JM, Kim KB, Tuttle JB, Steers WD. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J Urol. 2001; 166:1111–1118.

21. Chuang YC, Fraser MO, Yu Y, Chancellor MB, de Groat WC, Yoshimura N. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol. 2001; 165:975–979.

22. Lamb K, Gebhart GF, Bielefeldt K. Increased nerve growth factor expression triggers bladder overactivity. J Pain. 2004; 5:150–156.

23. Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004; 172:240–243.

24. Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int. 2010; 106:1681–1685.

25. Giannantoni A, Conte A, Farfariello V, Proietti S, Vianello A, Nardicchi V, et al. Onabotulinumtoxin-A intradetrusorial injections modulate bladder expression of NGF, TrkA, p75 and TRPV1 in patients with detrusor overactivity. Pharmacol Res. 2013; 68:118–124.

26. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003; 43 Suppl 1:S9–S15.

27. Cui M, Aoki KR. Botulinum toxic type a (BTX-A) reduces inflammatory pain in the rat formalin model. Cephalagia. 2000; 20:414.

28. Durham PL, Cady R, Cady R. Regulation of calcitonin generelated peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004; 44:35–42. discussion 42-3.

29. Kuo HC. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity. Neurourol Urodyn. 2011; 30:1497–1502.

30. Jiang YH, Liu HT, Kuo HC. Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. PLoS One. 2014; 9:e91609.

31. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. American Urological Association. Society of Urodynamics, Female Pelvic Medicine. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015; 193:1572–1580.

32. Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU Guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2018; 73:596–609.

33. Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology. 2004; 63 (3 Suppl 1):17–23.

34. Sun Y, Chai TC. Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J Urol. 2004; 171:448–452.

35. Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, Anand P. Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology. 2005; 65:400–405.

36. Avelino A, Cruz C, Nagy I, Cruz F. Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience. 2002; 109:787–798.

37. Lawrence GW, Aoki KR, Dolly JO. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. J Pharmacol Exp Ther. 2010; 334:1080–1086.

38. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007; 177:2231–2236.

39. Jeffery S, Fynes M, Lee F, Wang K, Williams L, Morley R. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int. 2007; 100:1302–1306.

40. Rajkumar GN, Small DR, Mustafa AW, Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 2005; 96:848–852.

41. Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol. 2005; 174:984–989.

42. Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology. 2006; 68:993–997. discussion 997-8.

43. Werner M, Schmid DM, Schüssler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol. 2005; 192:1735–1740.

44. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010; 184:2416–2422.

45. Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al. VESITOX study group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012; 61:520–529.

46. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011; 30:556–562.

47. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013; 189:2186–2193.

48. Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013; 64:249–256.

49. Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014; 65:981–990.

50. Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011; 186:960–964.

51. Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease. Urology. 2014; 83:22–27.

52. Çetinel B, Tarcan T, Demirkesen O, Özyurt C, Şen İ, Erdoğan S, et al. Management of lower urinary tract dysfunction in multiple sclerosis: a systematic review and Turkish consensus report. Neurourol Urodyn. 2013; 32:1047–1057.

53. Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology. 2006; 67:232–236.

54. Wang CC, Liao CH, Kuo HC. Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxinA injection in patients with refractory detrusor overactivity. Neurourol Urodyn. 2014; 33:1235–1239.

55. Hsiao SM, Lin HH, Kuo HC. Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome. PLoS One. 2016; 11:e0147137.

56. Ke QS, Kuo HC. Pathophysiology of interstitial cystitis/bladder pain syndrome. Tzu Chi Med J. 2015; 27:139–144.

57. Shie JH, Liu HT, Kuo HC. Increased cell apoptosis of urothelium mediated by inflammation in interstitial cystitis/painful bladder syndrome. Urology. 2012; 79:484.e7–484.e13.

58. Shie JH, Kuo HC. Higher levels of cell apoptosis and abnormal E-cadherin expression in the urothelium are associated with inflammation in patients with interstitial cystitis/painful bladder syndrome. BJU Int. 2011; 108(2 Pt 2):E136–E141.

59. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009; 104:657–661.

60. Lundeberg T, Liedberg H, Nordling L, Theodorsson E, Owzarski A, Ekman P. Interstitial cystitis: correlation with nerve fibres, mast cells and histamine. Br J Urol. 1993; 71:427–429.

61. Li WW, Guo TZ, Liang DY, Sun Y, Kingery WS, Clark JD. Substance P signaling controls mast cell activation, degranulation, and nociceptive sensitization in a rat fracture model of complex regional pain syndrome. Anesthesiology. 2012; 116:882–895.

62. Yamada T, Nishimura M, Mita H. Increased number of apoptotic endothelial cells in bladder of interstitial cystitis patients. World J Urol. 2007; 25:407–413.

63. Rong W, Spyer KM, Burnstock G. Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder. J Physiol. 2002; 541(Pt 2):591–600.

64. Homma Y, Nomiya A, Tagaya M, Oyama T, Takagaki K, Nishimatsu H, et al. Increased mRNA expression of genes involved in pronociceptive inflammatory reactions in bladder tissue of interstitial cystitis. J Urol. 2013; 190:1925–1931.

65. Shea VK, Cai R, Crepps B, Mason JL, Perl ER. Sensory fibers of the pelvic nerve innervating the Rat's urinary bladder. J Neurophysiol. 2000; 84:1924–1933.

66. Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004; 64:871–875. discussion 875.

67. Kuo HC. Preliminary results of suburothelial injection of botulinum A toxin in the treatment of chronic interstitial cystitis. Urol Int. 2005; 75:170–174.

68. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006; 49:704–709.

69. Ramsay AK, Small DR, Conn IG. Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. Surgeon. 2007; 5:331–333.

70. Giannantoni A, Cagini R, Del Zingaro M, Proietti S, Quartesan R, Porena M, et al. Botulinum A toxin intravesical injections for painful bladder syndrome: impact upon pain, psychological functioning and Quality of Life. Curr Drug Deliv. 2010; 7:442–446.

71. Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Physician. 2012; 15:197–202.

72. Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician. 2013; 16:E15–E23.

73. Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010; 58:360–365.

74. Pinto R, Lopes T, Silva J, Silva C, Dinis P, Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol. 2013; 189:548–553.

75. Lee CL, Kuo HC. Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician. 2013; 16:109–116.

76. Pinto R, Lopes T, Costa D, Barros S, Silva J, Silva C, et al. Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A. Urology. 2014; 83:1030–1034.

77. Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016; 35:609–614.

78. Hanno PM, Erickson D, Moldwin R, Faraday MM. American Urological Association. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015; 193:1545–1553.

79. Homma Y, Ueda T, Tomoe H, Lin AT, Kuo HC, Lee MH, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. Int J Urol. 2016; 23:542–549.

80. Nigro DA, Wein AJ, Foy M, Parsons CL, Williams M, Nyberg LM Jr, et al. Associations among cystoscopic and urodynamic findings for women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology. 1997; 49(5A Suppl):86–92.

81. Denson MA, Griebling TL, Cohen MB, Kreder KJ. Comparison of cystoscopic and histological findings in patients with suspected interstitial cystitis. J Urol. 2000; 164:1908–1911.

82. Tomaszewski JE, Landis JR, Russack V, Williams TM, Wang LP, Hardy C, et al. Interstitial Cystitis Database Study Group. Biopsy features are associated with primary symptoms in interstitial cystitis: results from the interstitial cystitis database study. Urology. 2001; 57(6 Suppl 1):67–81.

83. Peters KM, Killinger KA, Mounayer MH, Boura JA. Are ulcerative and nonulcerative interstitial cystitis/painful bladder syndrome 2 distinct diseases? A study of coexisting conditions. Urology. 2011; 78:301–308.

84. Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, et al. Interstitial Cystitis Guidelines Panel of the American Urological Association Education and Research, Inc. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011; 185:2162–2170.

85. Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. European Consensus Panel. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009; 55:100–119.

86. Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005; 174:196–200.

87. Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol. 2012; 61:834–839.

88. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol. 2010; 58:919–926.

89. Kuo YC, Kuo HC. Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis--different mechanisms of action of botox on bladder dysfunction? Toxins (Basel). 2016; 8:E75.

90. Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011; 30:1242–1248.

91. Tyagi P, Chancellor MB, Li Z, De Groat WC, Yoshimura N, Fraser MO, et al. Urodynamic and immunohistochemical evaluation of intravesical capsaicin delivery using thermosensitive hydrogel and liposomes. J Urol. 2004; 171:483–489.

92. Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L, et al. Intravesical liposome administration--a novel treatment for hyperactive bladder in the rat. Urology. 2003; 61:656–663.

93. Chuang YC, Tyagi P, Huang CC, Yoshimura N, Wu M, Kaufman J, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009; 182:786–792.

94. Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: a single-center study. Eur Urol. 2014; 65:1117–1124.

95. Liu HT, Chen SH, Chancellor MB, Kuo HC. Presence of cleaved synaptosomal-associated protein-25 and decrease of purinergic receptors P2X3 in the bladder urothelium influence efficacy of botulinum toxin treatment for overactive bladder syndrome. PLoS One. 2015; 10:e0134803.

96. Chuang YC, Kaufmann JH, Chancellor DD, Chancellor MB, Kuo HC. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urol. 2014; 192:1743–1749.

97. Tyagi P, Hsieh VC, Yoshimura N, Kaufman J, Chancellor MB. Instillation of liposomes vs dimethyl sulphoxide or pentosan polysulphate for reducing bladder hyperactivity. BJU Int. 2009; 104:1689–1692.

98. Chuang YC, Lee WC, Lee WC, Chiang PH. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J Urol. 2009; 182:1393–1400.

99. Chuang YC, Kuo HC. A prospective, multicenter, double-blind, randomized trial of bladder instillation of liposome formulation onabotulinumtoxinA for interstitial cystitis/bladder pain syndrome. J Urol. 2017; 198:376–382.